Biotech Values

[jbog]

Amarin raises FY19 revenue view to $410M-$425M from $380M-$420M FY19 consensus $410.25M.


Amarin sees FY20 revenue $650M-$700M,

consensus $654.55M With respect to 2020, Amarin projects that total net revenue will be in a range of $650M-$700M, mostly from sales of Vascepa in the United States. Amarin is providing this projected revenue guidance for 2020 and has based its projection on a number of factors, including, but not limited to, expectations on market acceptance of the newly expanded label for Vascepa and current plans for expanded promotion. Vascepa revenues are anticipated to continue to increase in 2020, accompanied by quarterly industry variability, including recurring seasonal factors, particularly in the first quarter. Given that it takes time to educate providers and patients, Amarin expects a delayed impact from planned promotional programs either because they are new, such as the impact of new sales representatives, or, in the case of direct-to-consumer promotion, because separate regulatory approval is required and not currently expected until mid-2020. In addition, while multiple studies have concluded that Vascepa is cost effective, how managed care organizations will react to a cost-effective therapy lacks adequate precedent. Beyond 2020, Amarin believes that Vascepa total net revenue will grow to reach multiple billions of dollars. However, the history of other therapies for chronic conditions suggests that growth builds over multiple years. At this time, the company is not providing guidance regarding annual revenue levels beyond 2020.

Read more at:
https://thefly.com/landingPageNews.php?id=3006874